D-0510-2023 Class III Terminated

Recalled by Teva Pharmaceuticals USA Inc — Parsippany, NJ

FDA drug recall D-0510-2023 was initiated by Teva Pharmaceuticals USA Inc on Mar 27, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A. The recall status is terminated (terminated Aug 23, 2023). Affected quantity: 3,772 cartons.

Recall details

Product Type
Drugs
Report Date
Apr 12, 2023
Initiation Date
Mar 27, 2023
Termination Date
Aug 23, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,772 cartons

Product description

Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19

Reason for recall

Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

Distribution pattern

USA Nationwide

Code information

Lot # 3007556A, Exp 5/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0510-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0510-2023. Report a data issue: hello@regdatalab.com.